Wang Ke-Jie, Wang Kai-Yun, Zhang Hui-Zhi, Meng Xiang-Yu, Chen Jun-Feng, Wang Ping, Jiang Jun-Hui, Ma Qi
Translational Research Laboratory for Urology, The Key Laboratory of Ningbo City, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, China.
Comprehensive Urogenital Cancer Center, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, China.
Front Oncol. 2020 Aug 26;10:1720. doi: 10.3389/fonc.2020.01720. eCollection 2020.
The receptor-interacting protein kinase 3 (RIP3/RIPK3) was recently found to be a critical regulator of programmed necrosis/necroptosis. However, the biological role and clinical significance of RIP3 in prostate cancer remain obscure.
Western blotting and QRT-PCR were performed to detect the level of RIP3 in prostate cancer cells. Fixed cancer tissue and normal tissue specimens were subjected to immunohistochemical analysis of RIP3. Cell migration and invasion abilities were evaluated by transwell assays. proliferative ability was examed by MTS. And nude mice model were used to evaluate the effect of RIP3 ectopic expression on proliferative capability. Cell cycle of prostate cancer cells were analyzed by flow cytometry. Changes in some related proteins caused by RIP3 overexpression were explored using Western blotting.
RIP3 was significantly down-regulated in prostate cancer cell lines and clinical prostate tumor samples. And over-expressing RIP3 suppressed the migration and invasion of prostate cancer cells. Two important matrix metalloproteinases MMP2, MMP9 which enables the destruction of the histological barrier of tumor cell invasion and three mesenchymal markers Vimentin, fibronectin, and N-cadherin were under-expressed due to the overexpression of RIP3, but the E-cadherin level which is the epithelial marker was increased. Furthermore, our results also showed that RIP3 can inhibit the proliferation and tumorigenicity of prostate cancer cells both and by phosphorylating MLKL, which were reversed by MLKL inhibitor treatment, indicating that necroptosis was involved in cell death.
Taken together, these findings indicated that RIP3 is responsible for the progression of prostate cancer, suggesting that RIP3 might have the potential to be a prognostic marker or a therapeutic target against prostate cancer.
最近发现受体相互作用蛋白激酶3(RIP3/RIPK3)是程序性坏死/坏死性凋亡的关键调节因子。然而,RIP3在前列腺癌中的生物学作用和临床意义仍不清楚。
采用蛋白质免疫印迹法和定量逆转录聚合酶链反应(QRT-PCR)检测前列腺癌细胞中RIP3的水平。对固定的癌组织和正常组织标本进行RIP3免疫组织化学分析。通过Transwell实验评估细胞迁移和侵袭能力。用MTS检测增殖能力。利用裸鼠模型评估RIP3异位表达对增殖能力的影响。通过流式细胞术分析前列腺癌细胞的细胞周期。使用蛋白质免疫印迹法探索由RIP3过表达引起的一些相关蛋白的变化。
RIP3在前列腺癌细胞系和临床前列腺肿瘤样本中显著下调。过表达RIP3可抑制前列腺癌细胞的迁移和侵袭。由于RIP3过表达,两种重要的基质金属蛋白酶MMP2、MMP9(其可破坏肿瘤细胞侵袭的组织学屏障)以及三种间充质标志物波形蛋白、纤连蛋白和N-钙黏蛋白表达下调,但上皮标志物E-钙黏蛋白水平升高。此外,我们的结果还表明,RIP3可通过磷酸化混合谱系激酶结构域样蛋白(MLKL)抑制前列腺癌细胞的增殖和致瘤性,而MLKL抑制剂处理可逆转这种作用,表明坏死性凋亡参与细胞死亡。
综上所述,这些发现表明RIP3与前列腺癌的进展有关,提示RIP3可能有潜力成为前列腺癌的预后标志物或治疗靶点。